The National Surgical Adjuvant Breast and Bowel Project (NSABP) is an NCI-funded clinical trials cooperative group for cancer treatment and prevention and control research. The group has a more than 40-year history of conducting large-scale controlled treatment trials that have improved the outcome for patients with breast or colorectal cancer and have provided a better understanding of tumor biology. In 1992, the NSABP extended its research agenda to include cancer prevention trials. The NSABP has been a CCOP Research Base since the inception of the CCOP Program and 45 CCOPs and 8 MBCCOPs currently list the NSABP among their research bases. CCOP participation in NSABP treatment and prevention trials is substantial;approximately 30% of NSABP accrual is attributable to CCOP investigators. This application requests continued funding for the NSABP to continue as a CCOP Research Base for the period of June 1, 2012, through May 31, 2017. During the proposed grant period, the NSABP will 1) continue to design and implement multi-institutional cancer treatment and prevention and control clinical trials;2) analyze, report, and publish the results of current NSABP studies;3) implement recruitment mechanisms and procedures to achieve adequate accrual and foster the participation of women and minorities in NSABP clinical trials;4) maintain data collection, data monitoring, and quality control procedures that are in compliance with federal guidelines;5) monitor CCOP performance through ongoing quality assurance programs;and, 6) continue the integration of CCOP investigators into the overall functioning of the NSABP.

Public Health Relevance

Breast and bowel represents a major public health issue with a combined incidence of 361,530 cases in the United States in 2010 and more than 96,140 deaths attributed to the cancers. The NSABP has a 50+ year history of conducting high quality cancer, treatment, prevention, and control clinical trials that have substantially improved the survival and the quality of life of individuals with these diseases. This application will allow th NSABP to continue this important research that has the potential to impact the care of women and men in the United States and around the world.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-B (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Nsabp Foundation, Inc.
United States
Zip Code
Ribi, Karin; Luo, Weixiu; Bernhard, Jürg et al. (2016) Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol 34:1601-10
Land, Stephanie R; Walcott, Farzana L; Liu, Qing et al. (2016) Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1. J Natl Cancer Inst 108:
Regan, Meredith M; Francis, Prudence A; Pagani, Olivia et al. (2016) Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol 34:2221-31
Wolmark, Norman; Mamounas, Eleftherios P; Baehner, Frederick L et al. (2016) Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/Nati J Clin Oncol 34:2350-8
Dalerba, Piero; Sahoo, Debashis; Paik, Soonmyung et al. (2016) CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med 374:211-22
Johansson, Harriet; Gray, Kathryn P; Pagani, Olivia et al. (2016) Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Res 18:110
Chapman, Judith-Anne W; Costantino, Joseph P; Dong, Bin et al. (2015) Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. Breast Cancer Res Treat 153:353-60
Wickerham, D Lawrence; Vogel, Victor G (2015) Breast cancer chemoprevention: the saga of underuse continues. J Natl Cancer Inst 107:399
Minasian, Lori M; Tangen, Catherine M; Wickerham, D Lawrence (2015) Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. Semin Oncol 42:748-63
Vachon, Celine M; Schaid, Daniel J; Ingle, James N et al. (2015) A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. Breast Cancer Res Treat 149:517-23

Showing the most recent 10 out of 232 publications